Research memoJohnson & Johnson (JNJ) · NYSEMemo of October 14, 2026

Johnson & Johnson dividend: cash flow and yield

Johnson & Johnson's dividend is forecast to rise from $5.44 per share to $5.77 in the base case. Johnson & Johnson generated $19,536 million of free cash flow in 2025, while its large shareholder payments left little annual surplus for acquisitions.

5.10
Dividend paid per share, 2025
2.2%
Dividend yield
3.0%
Real free cash flow yield
3.3%
Free cash flow yield
Read the full Johnson & Johnson memoYour first report is free · no card
Every number traced to Johnson & Johnson's filings8 chapters · 17,085 words274 sources cited

How much does Johnson & Johnson pay per share?

Dividends rise from $5.44 per share to $5.77 in the base case, near the latest 3.1% increase. The bear case holds $5.36 throughout, a pause rather than a cut. The bull case reaches $5.92 because stronger cash generation permits faster increases. J&J's 64-year record of consecutive increases and 2026 free-cash-flow guidance support continued growth, but talc payments and debt limit confidence.

Dividend per share against free cash flow per share (US$ per share, except percentages)4.13Jan 20224.39Jan 20234.6020234.877.6120245.107.482025Dividends paid, per shareReal free cash flow per share
The forecast's tablebase case, then bear / bull in brackets; USD millions, per share in USD, unless shown
October 2027October 2028October 2029
Earnings29,992 (26,520 / 30,738)31,275 (26,625 / 33,696)32,665 (26,705 / 36,500)
Shares (millions)2,411 (2,414 / 2,400)2,412 (2,418 / 2,388)2,414 (2,422 / 2,373)
Dividends per share5.44 (5.36 / 5.50)5.60 (5.36 / 5.70)5.77 (5.36 / 5.92)
Price to earnings19.00 (16.00 / 22.00)19.00 (14.00 / 24.00)19.00 (13.00 / 25.00)

Is Johnson & Johnson's dividend covered by its cash?

Profit records accounting income; cash flow records money collected and paid. J&J’s operating cash flow was $24,530 million in 2025, while free cash flow after capital spending was $19,536 million. A sale may be recorded before the customer pays, and inventory may consume cash before it is sold.

Dividends distribute cash to owners, while buybacks purchase shares and can increase each remaining share’s claim on future earnings. J&J’s large shareholder payments left little annual surplus for acquisitions. That matters because acquisitions still required substantial cash, while sales of businesses and assets supplied much less.

Follow the money: where the free cash flow wentUS$ millions
202520242023Jan 2023Jan 2022
Free cash flow19,53619,668
− Dividends paid12,38111,82311,77011,68211,032
− Share buybacks5,9532,4325,0546,0353,456
= Free cash flow not paid out1,2025,413
Paid out, % of free cash flow93.8%72.5%

What this means. Johnson & Johnson's own net debt is slightly different because it rounds its numbers, while our calculation uses the amounts shown.

What is Johnson & Johnson's dividend yield against its price?

At $248.61, shareholders value J&J’s equity at $599,125 million. Enterprise value is $627,403 million because it adds net debt to the equity value. The difference is like buying a house while taking responsibility for its mortgage: the shares belong to investors, but the operating business must also support lenders. The EV-to-revenue multiple therefore values the whole business, not merely the stock.

Finally, J&J’s 3.3% free-cash-flow yield is not all available for dividends. Debt repayment, acquisitions, research, and legal settlements compete for that cash. The proposed $5.5 billion talc resolution could require as much as $3 billion in 2027, so valuation must move from today’s measures to the company’s history.

What an investor pays todayUS$ millions
Today (Oct 14, 2026)
Share price248.61
Free cash flow yield (calculated)3.3%
Dividend yield (calculated)2.2%

What this means. The share price is from the market's close on October 13, even though the table is dated October 14.

From the full memo · 1. The business

Johnson & Johnson is a healthcare company that sells prescription medicines and medical devices. Its dollar comes in when a product reaches a paying customer, and goes out through research, manufacturing, distribution, people, partners, and investment.

Continue reading, free
Your first report is free · no card

Where these numbers come from

More on Johnson & Johnson

Johnson & Johnson stock forecastJohnson & Johnson earnings

Its rivals

Merck (MRK)Bristol Myers Squibb (BMY)Lilly (LLY)Medtronic (MDT)

Browse

All stocksS&P 500 companiesCompanies J
The full Johnson & Johnson memoYour first report is free
Read it